David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
This comes after the FDA said in October that Eli Lilly weight-loss treatments Mounjaro and Zepbound (which use the active ingredient tirzepatide, rather than semaglutide) were no longer on its list ...
The FDA announced the end of the shortage of Novo Nordisk's drugs, Wegovy and Ozempic, which will impact sales of cheaper compounded versions. Compounded copies of Eli Lilly's drugs, Zepbound and ...
1hon MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
13h
Stocktwits on MSNEli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results